| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 81 | 2023 | 565 | 9.520 |
Why?
|
| Psychomotor Agitation | 31 | 2019 | 63 | 3.730 |
Why?
|
| Dementia | 23 | 2023 | 158 | 3.100 |
Why?
|
| Apathy | 10 | 2021 | 28 | 2.910 |
Why?
|
| Methylphenidate | 7 | 2021 | 97 | 2.350 |
Why?
|
| Antipsychotic Agents | 19 | 2016 | 247 | 2.340 |
Why?
|
| Psychotic Disorders | 12 | 2012 | 157 | 1.930 |
Why?
|
| Citalopram | 14 | 2019 | 29 | 1.740 |
Why?
|
| Risperidone | 9 | 2016 | 48 | 1.500 |
Why?
|
| Aged | 87 | 2023 | 14842 | 1.190 |
Why?
|
| Geriatric Psychiatry | 4 | 2014 | 9 | 1.080 |
Why?
|
| Central Nervous System Stimulants | 4 | 2021 | 221 | 1.000 |
Why?
|
| Double-Blind Method | 40 | 2021 | 1738 | 0.920 |
Why?
|
| Aged, 80 and over | 46 | 2021 | 4843 | 0.910 |
Why?
|
| Cholinesterase Inhibitors | 10 | 2021 | 58 | 0.760 |
Why?
|
| Aggression | 11 | 2016 | 98 | 0.750 |
Why?
|
| Sertraline | 9 | 2014 | 62 | 0.750 |
Why?
|
| Humans | 115 | 2023 | 68549 | 0.740 |
Why?
|
| Psychiatric Status Rating Scales | 21 | 2019 | 782 | 0.730 |
Why?
|
| Nootropic Agents | 5 | 2012 | 18 | 0.690 |
Why?
|
| Depression | 10 | 2016 | 942 | 0.690 |
Why?
|
| Driving Under the Influence | 1 | 2018 | 1 | 0.660 |
Why?
|
| Male | 77 | 2023 | 37283 | 0.650 |
Why?
|
| Caregivers | 11 | 2020 | 365 | 0.640 |
Why?
|
| Female | 76 | 2023 | 38021 | 0.640 |
Why?
|
| Mental Disorders | 5 | 2010 | 659 | 0.590 |
Why?
|
| Antidepressive Agents | 7 | 2015 | 216 | 0.580 |
Why?
|
| Attention | 2 | 2013 | 225 | 0.490 |
Why?
|
| Neuropsychological Tests | 17 | 2016 | 517 | 0.460 |
Why?
|
| Cohort Studies | 6 | 2021 | 2356 | 0.430 |
Why?
|
| Treatment Outcome | 31 | 2018 | 7028 | 0.420 |
Why?
|
| Cognition Disorders | 8 | 2014 | 342 | 0.390 |
Why?
|
| Memantine | 5 | 2014 | 10 | 0.390 |
Why?
|
| Dibenzothiazepines | 3 | 2007 | 15 | 0.390 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2013 | 128 | 0.390 |
Why?
|
| Antidepressive Agents, Second-Generation | 5 | 2016 | 53 | 0.390 |
Why?
|
| Behavioral Symptoms | 4 | 2018 | 32 | 0.380 |
Why?
|
| Registries | 3 | 2023 | 730 | 0.360 |
Why?
|
| Benzodiazepines | 4 | 2008 | 130 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2018 | 929 | 0.360 |
Why?
|
| Indans | 6 | 2012 | 20 | 0.360 |
Why?
|
| Alcoholism | 1 | 2018 | 1109 | 0.350 |
Why?
|
| Galantamine | 3 | 2007 | 9 | 0.350 |
Why?
|
| Middle Aged | 31 | 2023 | 21119 | 0.350 |
Why?
|
| Severity of Illness Index | 16 | 2018 | 1851 | 0.350 |
Why?
|
| Institutionalization | 3 | 2007 | 7 | 0.350 |
Why?
|
| Piperidines | 6 | 2012 | 123 | 0.340 |
Why?
|
| Basal Ganglia Diseases | 4 | 2006 | 13 | 0.330 |
Why?
|
| Vascular Diseases | 1 | 2008 | 94 | 0.310 |
Why?
|
| Cross-Cultural Comparison | 3 | 2007 | 68 | 0.310 |
Why?
|
| Cognition | 7 | 2020 | 512 | 0.300 |
Why?
|
| South Carolina | 6 | 2023 | 2752 | 0.300 |
Why?
|
| Mental Health Services | 2 | 2013 | 199 | 0.290 |
Why?
|
| Quinolones | 1 | 2007 | 60 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2016 | 1745 | 0.280 |
Why?
|
| Hallucinations | 2 | 2016 | 19 | 0.280 |
Why?
|
| Public Health | 1 | 2008 | 201 | 0.280 |
Why?
|
| Needs Assessment | 2 | 2005 | 186 | 0.280 |
Why?
|
| Patient Selection | 2 | 2014 | 592 | 0.270 |
Why?
|
| Piperazines | 1 | 2007 | 206 | 0.270 |
Why?
|
| Pirenzepine | 3 | 2002 | 17 | 0.270 |
Why?
|
| Rivastigmine | 2 | 2021 | 6 | 0.270 |
Why?
|
| Anxiety | 2 | 2016 | 422 | 0.270 |
Why?
|
| Veterans | 3 | 2021 | 904 | 0.260 |
Why?
|
| Hypnotics and Sedatives | 2 | 2015 | 96 | 0.260 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 176 | 0.260 |
Why?
|
| Depressive Disorder | 5 | 2012 | 621 | 0.250 |
Why?
|
| Cultural Diversity | 1 | 2005 | 67 | 0.250 |
Why?
|
| Serotonin | 3 | 2003 | 144 | 0.250 |
Why?
|
| Referral and Consultation | 2 | 2004 | 383 | 0.240 |
Why?
|
| Primary Health Care | 3 | 2021 | 702 | 0.240 |
Why?
|
| Consensus | 2 | 2021 | 211 | 0.240 |
Why?
|
| Activities of Daily Living | 10 | 2018 | 319 | 0.240 |
Why?
|
| Critical Pathways | 1 | 2004 | 33 | 0.240 |
Why?
|
| Aging | 4 | 2015 | 911 | 0.240 |
Why?
|
| Remote Consultation | 1 | 2004 | 50 | 0.240 |
Why?
|
| Violence | 1 | 2006 | 275 | 0.230 |
Why?
|
| Vitamin E | 2 | 2014 | 55 | 0.230 |
Why?
|
| Parasympathomimetics | 1 | 2003 | 13 | 0.220 |
Why?
|
| Combat Disorders | 1 | 2004 | 102 | 0.220 |
Why?
|
| Cholesterol | 1 | 2004 | 331 | 0.220 |
Why?
|
| Psychotropic Drugs | 3 | 2016 | 83 | 0.210 |
Why?
|
| Clozapine | 3 | 1997 | 46 | 0.210 |
Why?
|
| Environmental Exposure | 1 | 2004 | 269 | 0.200 |
Why?
|
| Behavior Therapy | 4 | 1997 | 297 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 1 | 2003 | 102 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 2265 | 0.200 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 848 | 0.200 |
Why?
|
| Nursing Homes | 4 | 2006 | 54 | 0.190 |
Why?
|
| Neurocognitive Disorders | 1 | 2021 | 23 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2021 | 62 | 0.190 |
Why?
|
| Antioxidants | 2 | 2014 | 304 | 0.190 |
Why?
|
| United States | 7 | 2018 | 7338 | 0.190 |
Why?
|
| Expert Testimony | 1 | 2021 | 47 | 0.190 |
Why?
|
| Diet | 1 | 2004 | 514 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 239 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2023 | 7268 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2021 | 105 | 0.170 |
Why?
|
| Research Design | 3 | 2013 | 729 | 0.170 |
Why?
|
| Fenfluramine | 1 | 1998 | 6 | 0.170 |
Why?
|
| Serotonin Agents | 1 | 1998 | 13 | 0.170 |
Why?
|
| Law Enforcement | 1 | 2018 | 10 | 0.160 |
Why?
|
| Polypharmacy | 3 | 2003 | 31 | 0.160 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2018 | 151 | 0.160 |
Why?
|
| Day Care, Medical | 1 | 1997 | 18 | 0.150 |
Why?
|
| Placebos | 5 | 2015 | 195 | 0.150 |
Why?
|
| Automobile Driving | 1 | 2018 | 88 | 0.150 |
Why?
|
| Dementia, Multi-Infarct | 1 | 1997 | 2 | 0.150 |
Why?
|
| Advisory Committees | 1 | 2018 | 73 | 0.150 |
Why?
|
| Interview, Psychological | 1 | 1998 | 113 | 0.150 |
Why?
|
| Apolipoproteins E | 3 | 2015 | 92 | 0.150 |
Why?
|
| Ciprofloxacin | 1 | 1997 | 30 | 0.150 |
Why?
|
| Schizophrenia | 3 | 2007 | 206 | 0.150 |
Why?
|
| Drug Administration Schedule | 6 | 2013 | 567 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2016 | 435 | 0.150 |
Why?
|
| Telephone | 1 | 1998 | 160 | 0.150 |
Why?
|
| Disease Progression | 4 | 2015 | 1037 | 0.140 |
Why?
|
| Drug Therapy, Combination | 7 | 2014 | 648 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2550 | 0.140 |
Why?
|
| Dopamine Agents | 2 | 2014 | 56 | 0.140 |
Why?
|
| Confusion | 1 | 1996 | 20 | 0.140 |
Why?
|
| Azepines | 1 | 2016 | 15 | 0.140 |
Why?
|
| Alanine | 1 | 2016 | 38 | 0.140 |
Why?
|
| Delusions | 1 | 2016 | 20 | 0.140 |
Why?
|
| Irritable Mood | 1 | 2016 | 15 | 0.140 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2006 | 257 | 0.140 |
Why?
|
| Managed Care Programs | 1 | 1996 | 45 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2016 | 59 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 1997 | 170 | 0.130 |
Why?
|
| Dextromethorphan | 1 | 2015 | 5 | 0.130 |
Why?
|
| Anomia | 1 | 2015 | 9 | 0.130 |
Why?
|
| Quinidine | 1 | 2015 | 15 | 0.130 |
Why?
|
| Placebo Effect | 1 | 2015 | 20 | 0.130 |
Why?
|
| Homes for the Aged | 3 | 2005 | 16 | 0.130 |
Why?
|
| 1-Naphthylamine | 1 | 1995 | 11 | 0.130 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1995 | 7 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 1997 | 166 | 0.130 |
Why?
|
| Receptors, Serotonin | 1 | 2015 | 74 | 0.130 |
Why?
|
| Fluoxetine | 1 | 1995 | 40 | 0.130 |
Why?
|
| Stilbenes | 1 | 2015 | 57 | 0.130 |
Why?
|
| Combined Modality Therapy | 5 | 2006 | 951 | 0.120 |
Why?
|
| Risk Factors | 7 | 2016 | 5720 | 0.120 |
Why?
|
| Dangerous Behavior | 1 | 1994 | 8 | 0.120 |
Why?
|
| Pyridines | 1 | 1996 | 261 | 0.120 |
Why?
|
| Nerve Growth Factor | 1 | 2014 | 54 | 0.120 |
Why?
|
| Yoga | 1 | 2014 | 18 | 0.120 |
Why?
|
| Length of Stay | 1 | 1997 | 780 | 0.120 |
Why?
|
| Respiration | 1 | 2014 | 91 | 0.120 |
Why?
|
| Adult | 9 | 2023 | 21379 | 0.120 |
Why?
|
| Age Factors | 4 | 2004 | 1860 | 0.110 |
Why?
|
| Clinical Protocols | 2 | 2012 | 172 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2008 | 266 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 659 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2013 | 107 | 0.110 |
Why?
|
| Program Development | 1 | 1994 | 240 | 0.110 |
Why?
|
| Anxiety Disorders | 1 | 1996 | 426 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 627 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 77 | 0.110 |
Why?
|
| Gender Identity | 1 | 1992 | 47 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2012 | 144 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 22 | 0.100 |
Why?
|
| Parent-Child Relations | 1 | 1992 | 98 | 0.100 |
Why?
|
| Withholding Treatment | 1 | 2012 | 35 | 0.100 |
Why?
|
| Heart Rate | 1 | 2014 | 568 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2013 | 1054 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2010 | 2222 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 1993 | 344 | 0.100 |
Why?
|
| Quetiapine Fumarate | 3 | 2007 | 20 | 0.100 |
Why?
|
| Mental Status Schedule | 4 | 2008 | 31 | 0.100 |
Why?
|
| Time Factors | 6 | 2021 | 4655 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 791 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2012 | 220 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2013 | 403 | 0.090 |
Why?
|
| Geriatric Assessment | 4 | 2014 | 107 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2014 | 824 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 506 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2009 | 955 | 0.090 |
Why?
|
| Comorbidity | 2 | 2008 | 1425 | 0.090 |
Why?
|
| Patient Care Team | 2 | 2004 | 311 | 0.080 |
Why?
|
| Quality of Life | 3 | 2014 | 1515 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2012 | 1040 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 786 | 0.080 |
Why?
|
| Biomarkers | 3 | 2010 | 1593 | 0.080 |
Why?
|
| Delirium | 2 | 2007 | 45 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 3256 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 581 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 3 | 2018 | 186 | 0.080 |
Why?
|
| Observer Variation | 1 | 2009 | 330 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2008 | 272 | 0.080 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2007 | 23 | 0.080 |
Why?
|
| Age Distribution | 1 | 2008 | 319 | 0.080 |
Why?
|
| Brain | 6 | 2015 | 2176 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2008 | 105 | 0.080 |
Why?
|
| Aripiprazole | 1 | 2007 | 43 | 0.070 |
Why?
|
| Phenylcarbamates | 1 | 2007 | 1 | 0.070 |
Why?
|
| Age of Onset | 1 | 2007 | 188 | 0.070 |
Why?
|
| Drug Costs | 1 | 2008 | 87 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2014 | 551 | 0.070 |
Why?
|
| Markov Chains | 1 | 2008 | 133 | 0.070 |
Why?
|
| Social Environment | 2 | 2007 | 182 | 0.070 |
Why?
|
| Recurrence | 3 | 2016 | 948 | 0.070 |
Why?
|
| Mortality | 1 | 2008 | 162 | 0.070 |
Why?
|
| Thiazoles | 1 | 2007 | 95 | 0.070 |
Why?
|
| Genotype | 3 | 2015 | 785 | 0.070 |
Why?
|
| Atrophy | 3 | 2015 | 112 | 0.070 |
Why?
|
| Life Style | 1 | 2008 | 338 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2006 | 53 | 0.070 |
Why?
|
| Dementia, Vascular | 2 | 2003 | 22 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 503 | 0.070 |
Why?
|
| Psychoanalytic Interpretation | 1 | 2005 | 1 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2005 | 93 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 317 | 0.060 |
Why?
|
| Resource Allocation | 1 | 2005 | 35 | 0.060 |
Why?
|
| Health Behavior | 1 | 2008 | 458 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 2004 | 298 | 0.060 |
Why?
|
| Professional-Patient Relations | 1 | 2005 | 71 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2008 | 3703 | 0.060 |
Why?
|
| Health Care Rationing | 1 | 2004 | 32 | 0.060 |
Why?
|
| Vietnam | 1 | 2004 | 36 | 0.060 |
Why?
|
| Lewy Body Disease | 1 | 2004 | 9 | 0.060 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2003 | 21 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2004 | 122 | 0.060 |
Why?
|
| MMPI | 1 | 2004 | 40 | 0.060 |
Why?
|
| Utilization Review | 1 | 2004 | 48 | 0.060 |
Why?
|
| Spain | 2 | 2014 | 34 | 0.060 |
Why?
|
| Parkinson Disease | 2 | 2004 | 272 | 0.060 |
Why?
|
| Receptors, Dopamine | 1 | 2003 | 119 | 0.060 |
Why?
|
| Rural Population | 1 | 2007 | 397 | 0.060 |
Why?
|
| Aspartic Acid | 1 | 2003 | 65 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 147 | 0.060 |
Why?
|
| Personality Inventory | 1 | 2004 | 197 | 0.060 |
Why?
|
| Phencyclidine | 1 | 2003 | 17 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 277 | 0.050 |
Why?
|
| Psychometrics | 2 | 2018 | 514 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 2798 | 0.050 |
Why?
|
| Dizocilpine Maleate | 1 | 2003 | 43 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2013 | 1506 | 0.050 |
Why?
|
| Communication | 1 | 2005 | 329 | 0.050 |
Why?
|
| Lorazepam | 1 | 2002 | 54 | 0.050 |
Why?
|
| Anti-Anxiety Agents | 1 | 2002 | 107 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2021 | 21 | 0.050 |
Why?
|
| Prefrontal Cortex | 2 | 2004 | 639 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2000 | 17 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 216 | 0.050 |
Why?
|
| Hippocampus | 1 | 2003 | 471 | 0.050 |
Why?
|
| Emotions | 1 | 2021 | 244 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2004 | 438 | 0.040 |
Why?
|
| Physostigmine | 1 | 1999 | 14 | 0.040 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2004 | 413 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2673 | 0.040 |
Why?
|
| Cost of Illness | 2 | 2014 | 204 | 0.040 |
Why?
|
| Prolactin | 1 | 1998 | 61 | 0.040 |
Why?
|
| Psychotherapy, Brief | 1 | 1997 | 30 | 0.040 |
Why?
|
| Prevalence | 2 | 2012 | 1609 | 0.040 |
Why?
|
| Acute Disease | 2 | 2002 | 658 | 0.040 |
Why?
|
| Patient Dropouts | 2 | 2010 | 98 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 84 | 0.040 |
Why?
|
| Diabetic Foot | 1 | 1997 | 33 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 561 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 38 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2016 | 9 | 0.040 |
Why?
|
| Appetite | 1 | 2016 | 16 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1997 | 289 | 0.030 |
Why?
|
| Isomerism | 1 | 2016 | 63 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 106 | 0.030 |
Why?
|
| Cost Control | 1 | 1996 | 34 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 55 | 0.030 |
Why?
|
| Self-Help Groups | 1 | 1996 | 38 | 0.030 |
Why?
|
| Trazodone | 1 | 1996 | 5 | 0.030 |
Why?
|
| Ondansetron | 1 | 1996 | 13 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Decision Trees | 1 | 1996 | 74 | 0.030 |
Why?
|
| Buspirone | 1 | 1996 | 36 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 55 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1996 | 108 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2015 | 169 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2015 | 51 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 536 | 0.030 |
Why?
|
| Switzerland | 1 | 2014 | 4 | 0.030 |
Why?
|
| Portugal | 1 | 2014 | 7 | 0.030 |
Why?
|
| Norway | 1 | 2014 | 18 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 94 | 0.030 |
Why?
|
| Netherlands | 1 | 2014 | 68 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 107 | 0.030 |
Why?
|
| Mind-Body Therapies | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sodium | 1 | 1995 | 161 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 420 | 0.030 |
Why?
|
| Psychophysiology | 1 | 2014 | 11 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2015 | 304 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 1994 | 32 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 1998 | 1549 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2014 | 12 | 0.030 |
Why?
|
| Brain Mapping | 2 | 2012 | 531 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1265 | 0.030 |
Why?
|
| United Kingdom | 1 | 2014 | 152 | 0.030 |
Why?
|
| Basal Forebrain | 1 | 2014 | 15 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 78 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 124 | 0.030 |
Why?
|
| Sleep | 1 | 2016 | 263 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2014 | 25 | 0.030 |
Why?
|
| Animals | 2 | 2004 | 20880 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2014 | 141 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 149 | 0.030 |
Why?
|
| Behavior | 1 | 1993 | 59 | 0.030 |
Why?
|
| Saliva | 1 | 2014 | 142 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 295 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 2013 | 62 | 0.030 |
Why?
|
| Motor Activity | 1 | 2016 | 621 | 0.030 |
Why?
|
| Cuba | 1 | 1992 | 8 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 248 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1994 | 234 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 621 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 103 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2077 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 91 | 0.030 |
Why?
|
| Program Evaluation | 1 | 1994 | 502 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 239 | 0.030 |
Why?
|
| Workload | 1 | 1992 | 103 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 161 | 0.020 |
Why?
|
| Visual Cortex | 1 | 2012 | 67 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 1140 | 0.020 |
Why?
|
| Genomics | 1 | 2012 | 168 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 240 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 1991 | 103 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 172 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 301 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 201 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 386 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1195 | 0.020 |
Why?
|
| Memory | 1 | 1991 | 214 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 2093 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2010 | 402 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 689 | 0.020 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2006 | 4 | 0.020 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2006 | 8 | 0.020 |
Why?
|
| Problem Solving | 1 | 2006 | 36 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2010 | 335 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2006 | 80 | 0.020 |
Why?
|
| Haloperidol | 1 | 2006 | 95 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 177 | 0.020 |
Why?
|
| Affect | 1 | 2006 | 218 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 1984 | 94 | 0.020 |
Why?
|
| Counseling | 1 | 2006 | 279 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1984 | 153 | 0.010 |
Why?
|
| Inositol | 1 | 2003 | 11 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1984 | 228 | 0.010 |
Why?
|
| Skull | 1 | 2004 | 63 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 423 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2005 | 132 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2004 | 137 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 2003 | 173 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 86 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 572 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2002 | 44 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 346 | 0.010 |
Why?
|
| Receptors, Nicotinic | 1 | 2001 | 41 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2004 | 339 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 276 | 0.010 |
Why?
|
| Basal Ganglia | 1 | 2001 | 45 | 0.010 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 28 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 260 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2001 | 236 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 1341 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 8904 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1999 | 120 | 0.010 |
Why?
|
| Neurons | 1 | 2003 | 881 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 1995 | 53 | 0.010 |
Why?
|
| Smoking | 1 | 2003 | 1449 | 0.010 |
Why?
|
| Bradycardia | 1 | 1995 | 45 | 0.010 |
Why?
|
| Accidental Falls | 1 | 1995 | 84 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 1533 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1992 | 96 | 0.010 |
Why?
|
| Stroke | 1 | 2003 | 2162 | 0.010 |
Why?
|
| Hospitalization | 1 | 1995 | 977 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1984 | 54 | 0.000 |
Why?
|
| Isoproterenol | 1 | 1984 | 163 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1984 | 223 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 765 | 0.000 |
Why?
|